Literature DB >> 25449566

DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia.

Hung-Cheng Lai1, Yu-Chi Wang2, Mu-Hsien Yu2, Rui-Lan Huang3, Chiou-Chung Yuan4, Kuan-Ju Chen5, Chia-Chun Wu6, Kai-Jo Chiang7, Tai-Kuang Chao8.   

Abstract

OBJECTIVE: Women with atypical hyperplasia (AH) are often found to have endometrial carcinoma (EC) at hysterectomy. The purpose of this study was to evaluate whether the hypermethylation of specific genes found by methylomic approaches to the study of gynecologic cancers is a biomarker for EC in women with AH.
METHODS: We evaluated the methylation of AJAP1, HS3ST2, SOX1, and PTGDR from 61 AH patients undergoing hysterectomy. Endometrial biopsy samples were analyzed by bisulfite conversion and quantitative methylation-specific polymerase chain reaction. A methylation index was used to predict the presence of cancer. To confirm the silencing effects of DNA methylation, immunohistochemical analysis of AJAP1, HS3ST2, and SOX1 was performed using tissue microarray.
RESULTS: Fourteen (23%) patients had EC at hysterectomy. AJAP1, HS3ST2, and SOX1 were highly methylated in the EC patients' biopsy samples (p≤0.023). AJAP1, HS3ST2, and SOX1 protein expression was significantly higher in patients with AH only (p≤0.038). The predictive value of AJAP1, HS3ST2, and SOX1 methylation for EC was 0.81, 0.72, and 0.70, respectively. Combined testing of both AJAP1 and HS3ST2 methylation had a positive predictive value of 56%, methylation of any one of AJAP1, SOX1, or HS3ST2 had a 100% negative predictive value.
CONCLUSIONS: Hypermethylation of AJAP1, HS3ST2, and SOX1 is predictive of EC in AH patients. Testing for methylation of these genes in endometrial biopsy samples may be a hysterectomy-sparing diagnostic tool. Validation of these new genes as biomarkers for AH screening in a larger population-based study is warranted.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical hyperplasia; Endometrial carcinoma; Endometrium; Epigenetics; Methylation

Mesh:

Substances:

Year:  2014        PMID: 25449566     DOI: 10.1016/j.ygyno.2014.10.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Authors:  Jamie N Bakkum-Gamez; Nicolas Wentzensen; Matthew J Maurer; Kieran M Hawthorne; Jesse S Voss; Trynda N Kroneman; Abimbola O Famuyide; Amy C Clayton; Kevin C Halling; Sarah E Kerr; William A Cliby; Sean C Dowdy; Benjamin R Kipp; Andrea Mariani; Ann L Oberg; Karl C Podratz; Viji Shridhar; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2015-02-10       Impact factor: 5.482

2.  Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance.

Authors:  Fan Yang; Dongchen Liu; Yupeng Deng; Jun Wang; Shuyu Mei; Shuang Ge; Hailing Li; Cuijuan Zhang; Tingguo Zhang
Journal:  Oncol Lett       Date:  2020-03-19       Impact factor: 2.967

Review 3.  Malignant tumors of the uterine corpus: molecular background of their origin.

Authors:  D Brany; D Dvorska; M Nachajova; P Slavik; T Burjanivova
Journal:  Tumour Biol       Date:  2015-08-26

4.  Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.

Authors:  Vered Stearns; Mary Jo Fackler; Seema A Khan; Saraswati Sukumar; Sidra Hafeez; Zoila Lopez Bujanda; Robert T Chatterton; Lisa K Jacobs; Nagi F Khouri; David Ivancic; Kara Kenney; Christina Shehata; Stacie C Jeter; Judith A Wolfman; Carola M Zalles; Peng Huang
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-03

5.  Alternative exon usage creates novel transcript variants of tumor suppressor SHREW-1 gene with differential tissue expression profile.

Authors:  Petra A B Klemmt; Eduard Resch; Isabell Smyrek; Knut Engels; Ernst H K Stelzer; Anna Starzinski-Powitz
Journal:  Biol Open       Date:  2016-11-15       Impact factor: 2.422

6.  Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.

Authors:  Tai-Kuang Chao; Tien-Shuo Huang; Yu-Ping Liao; Rui-Lan Huang; Po-Hsuan Su; Hueng-Yuan Shen; Hung-Cheng Lai; Yu-Chi Wang
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

7.  MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Marios A Diamantopoulos; Anthi Bouchla; Eirini Glezou; Efthymia Bazani; Vasiliki Pappa; Andreas Scorilas
Journal:  Dis Markers       Date:  2017-12-31       Impact factor: 3.434

8.  Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.

Authors:  Helen R Moinova; Thomas LaFramboise; James D Lutterbaugh; Apoorva Krishna Chandar; John Dumot; Ashley Faulx; Wendy Brock; Omar De la Cruz Cabrera; Kishore Guda; Jill S Barnholtz-Sloan; Prasad G Iyer; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Prashanti N Thota; Joseph E Willis; Amitabh Chak; Sanford D Markowitz
Journal:  Sci Transl Med       Date:  2018-01-17       Impact factor: 19.319

Review 9.  Developing a deeper insight into reproductive biomarkers.

Authors:  Braira Wahid; Hamid Bashir; Muhammad Bilal; Khansa Wahid; Aleena Sumrin
Journal:  Clin Exp Reprod Med       Date:  2017-12-31

10.  Methylomics of nitroxidative stress on precancerous cells reveals DNA methylation alteration at the transition from in situ to invasive cervical cancer.

Authors:  Po-Hsuan Su; Yao-Wen Hsu; Rui-Lan Huang; Yu-Chun Weng; Hui-Chen Wang; Yu-Chih Chen; Yueh-Ju Tsai; Chiou-Chung Yuan; Hung-Cheng Lai
Journal:  Oncotarget       Date:  2017-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.